“We believe entering both the European and Middle Eastern markets in recent weeks will drive demand for PromarkerD in 2021 and beyond,” said Richard Lipscombe, managing director of Perth, Australia-based Proteomics International, in a statement.
Article: Proteomics International Inks Israeli Distribution Deal for Diabetic Kidney Disease Immunoassay
